drugset / Trial / NCT03173365

The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients

NCT03173365

Phase 2 Terminated 2 enrolled Heinrich-Heine University, Duesseldorf
NaSingle-groupOpen-labelTreatment

Summary

Comparative analysis of the severity of Hand-Foot-Syndrome (HFS) of palms treated with brimonidine tartrate gel or with standard care Urea 10% containing lotion in cancer patients receiving antineoplastic therapy to show a preventive effect of cutaneous brimonidine treatment on severity of HFS symptoms.

Timeline

Start
2017-07-10
Primary completion
2018-12-31
Completion
2018-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.5 g Topical

Indications